Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Mirtazapine (AN) TM
Active ingredients: mirtazapine
What it is used for
Treatment of major depression including relapse prevention.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White, biconvex, capsule shaped film coated tablets with '10' debossed on one side and 'A' debossed on the other side..
Food interactions
For the active ingredient mirtazapine
- Take without regard to meals. Avoid alcohol.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March 1, 2019. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Over 65?
This medicine contains the active ingredients:
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
Pregnant or planning a pregnancy?
For the active ingredient mirtazapine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
Mirtazapine Sandoz Tablets - myDr.com.au
Mirtazapine Sandoz Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
SNRI (Serotonin Noradrenaline [Norepinephrine] Reuptake Inhibitor) antidepressants - BluePages
Find out about the types of SNRI antidepressants, how they work, side effects, and common dosages.
Read more on e-hub Web Services - Australian National University (ANU) website
Amphetamine withdrawal management :: SA Health
Amphetamine withdrawal management - appropriate processes for the management of amphetamine withdrawal.
Read more on SA Health website
An update on the treatment of rosacea | Australian Prescriber
Rosacea can be a challenging condition to treat. Tailoring therapies to the type of rosacea is an important part of management.
Read more on Australian Prescriber website
Huntington's disease (Huntington's chorea) information | myVMC
Huntington's disease is an inherited, progressive neurodengenerative disease. It causes slow loss of brain cells and symptoms including dementia.
Read more on myVMC – Virtual Medical Centre website
Top results
Mirtazapine versus other antidepressive agents for depression | Cochrane
Major depression is characterised by a persistent low mood and loss of interest and pleasure. These symptoms are often accompanied by loss of appetite, insomnia, fatigue, poor concentration, inappropriate guilty feelings and even suicide. Depression was the third leading cause of disease burden among all diseases experienced by humankind in 2002. Antidepressants are used in treatment for major depression. They are the mainstay of treatment. Among them, mirtazapine is known to have a unique pharmacological profile and thus is supposed to differ in its efficacy and adverse effects profile in comparison with other antidepressants.
Read more on Cochrane (Australasian Centre) website
Treatment for amphetamine withdrawal | Cochrane
Symptoms of amphetamine withdrawal during the initial days of abstinence from chronic amphetamine use can prompt individuals to return to regular drug use. No medications demonstrate significant effects over placebo in reducing symptoms of acute amphetamine withdrawal.
Read more on Cochrane (Australasian Centre) website
Paroxetine versus other anti-depressive agents for depression | Cochrane
Major depression is a severe mental illness characterised by a persistent and unreactive low mood and loss of all interest and pleasure, usually accompanied by a range of symptoms such as appetite change, sleep disturbance, fatigue, loss of energy, poor concentration, inappropriate guilt and morbid thoughts of death. Although medication and psychological treatments are both effective for major depression, antidepressant drugs remain the mainstay of treatment in moderate to severe major depression. However, head-to-head comparisons of such drugs provide contrasting findings as to whether they are effective.
Read more on Cochrane (Australasian Centre) website
Fluoxetine compared with other antidepressants for depression in adults | Cochrane
Depression is a severe mental illness characterised by a persistent low mood and loss of all interest and pleasure, usually accompanied by a range of symptoms such as appetite change, sleep disturbance and poor concentration. The predominant treatment options for depression are drugs and psychological therapies, but antidepressant drugs are the most common treatment for moderate to severe depression. Fluoxetine, one of the first new generation antidepressants, is an extremely popular drug treatment for depression. However, findings from studies comparing fluoxetine with other antidepressants are controversial. In this systematic review, the efficacy and tolerability of fluoxetine was compared with other antidepressants for the acute treatment of depression.
Read more on Cochrane (Australasian Centre) website
Drug therapy for obstructive sleep apnoea in adults | Cochrane
Obstructive sleep apnoea (OSA) is caused by collapse of the upper airway. The mainstay of medical treatment is continuous positive airways pressure (CPAP), delivered through a mask during sleep, aiming to keep the airway opened. Drug therapy has been proposed for individuals with mild OSA and those intolerant of CPAP.
Read more on Cochrane (Australasian Centre) website
Depression in dementia | Issue 6 | Volume 38 | Australian Prescriber
People with dementia of any type have a high incidence of major depression.
Read more on Australian Prescriber website
Sexual difficulties in the menopause - Australasian Menopause Society
Sexual difficulties can be life-long or recently acquired, but they are a common presentation at the menopause.
Read more on Australasian Menopause Society website
Prescribing for people in custody | Issue 5 | Volume 38 | Australian Prescriber
People who are, or have been, in custody often have multiple morbidities and multi-dimensional disadvantage. A thorough clinical evaluation and...
Read more on Australian Prescriber website
An update on the treatment of rosacea | Australian Prescriber
Rosacea can be a challenging condition to treat. Tailoring therapies to the type of rosacea is an important part of management.
Read more on Australian Prescriber website
Functional dyspepsia | Australian Prescriber
Distinguishing between functional dyspepsia and reflux disease can be challenging find out what to look out for and how to tailor treatment.
Read more on Australian Prescriber website
